Latest Investigation News

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.

Canadian Phosphate (ASX: CP8) has kicked off a 3,000-metre drilling campaign at its Wapiti Phosphate Project in British Columbia, aiming for a Mineral Resource Estimate by late 2026 that will support both traditional fertilizer and advanced battery material markets.

Minerals Exploration Limited has completed its first phase of diamond drilling at the historic Jubilee Gold Mine within the Waitekauri Gold Project, confirming multiple quartz-mineralised zones and exceptional high-grade rock chip assays. Exploration continues with promising results at the Invincible Gold and Glenorchy Tungsten projects.

West Wits Mining has achieved a major underground breakthrough at Qala Shallows, unlocking higher-grade ore zones, while completing a comprehensive ZAR 1.115 billion finance package that underpins its production ramp-up.

Electro Optic Systems (ASX:EOS) posted a 284% surge in first-half 2026 revenue to $169 million, driven by robust defence contracts and regional tensions. Its order book hit a historic $846 million, prompting an upgrade to full-year guidance and signalling strong momentum in counter-drone and laser weapon systems.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Australian Mines has fast-tracked its Flemington Scandium Project pre-feasibility study to explore scaling production from 60 to 180 tonnes per annum amid rising market demand. The study builds on a strong scoping study that valued the project at up to US$860 million NPV.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Delta Lithium delivered high-grade lithium drilling results at Mt Ida and uncovered significant fluorite mineralisation at Yinnetharra, while securing key tenement acquisitions and maintaining a strong cash position of $49.6 million.

Perpetual Resources has validated multiple high-grade tungsten zones at its Paraíba Project in Brazil, underpinning a strategic push into critical minerals with a planned follow-up exploration phase.